VEGFA and neoplasm: Vanucizumab (RO5520985) is a humanised immunoglobulin (Ig)G-1-like bispecific monoclonal antibody targeting both VEGF-A and Ang-2 that has shown anti-tumour, anti-angiogenic and anti-metastatic effects in preclinical studies (20).